Benzene Ring And The Phosphorus Bonded Directly To The Same Chalcogen (i.e., The Carbon Of The Phosphorus Ester Group Is Part Of A Benzene Ring) Patents (Class 558/200)
-
Patent number: 9000077Abstract: A phosphazene compound having a vinyl group is manufactured by a reaction between a vinyl compound and a phosphazene compound having a hydroxyl group and added to a resin composition for manufacturing a prepreg or a resin film so as to be applicable to copper-clad laminates and printed circuit boards to thereby achieve satisfactory circuit laminate properties, namely low coefficient of thermal expansion, low dielectric properties, heat resistant, fire resistant, and halogen-free.Type: GrantFiled: June 19, 2013Date of Patent: April 7, 2015Assignee: Elite Material Co., Ltd.Inventor: Chen-Yu Hsieh
-
Publication number: 20140323624Abstract: A phosphazene compound having a vinyl group is manufactured by a reaction between a vinyl compound and a phosphazene compound having a hydroxyl group and added to a resin composition for manufacturing a prepreg or a resin film so as to be applicable to copper-clad laminates and printed circuit boards to thereby achieve satisfactory circuit laminate properties, namely low coefficient of thermal expansion, low dielectric properties, heat resistant, fire resistant, and halogen-free.Type: ApplicationFiled: June 19, 2013Publication date: October 30, 2014Inventor: CHEN-YU HSIEH
-
Publication number: 20140309164Abstract: Deuterated nucleoside analogs of Formula (I) and the pharmaceutically acceptable salts thereof are provided by this disclosure The variables, e.g., B1, Y, R1, R2, R3, R3?, R4, R5, R6, R7, R8, and R9 carry definitions set forth in the disclosure. Compounds of Formula (I) are deuterated at one or more positions and the deuterium enrichment at each deuterated positions is at least 50%. Compounds and salts of Formula (I) are useful for treating viral infections, including HCV infections.Type: ApplicationFiled: April 14, 2014Publication date: October 16, 2014Applicant: Achillion Pharmaceuticals, Inc.Inventors: Milind Deshpande, Jason Allan Wiles, Akihiro Hashimoto, Avinash Phadke
-
Publication number: 20130281687Abstract: Disclosed herein are methods of preparing a phosphorothioate nucleotide analog, which are useful in treating diseases and/or conditions such as viral infections.Type: ApplicationFiled: March 18, 2013Publication date: October 24, 2013Inventors: ALIOS BIOPHARMA, INC., VERTEX PHARMACEUTICALS INC.
-
Publication number: 20130165644Abstract: Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.Type: ApplicationFiled: January 25, 2013Publication date: June 27, 2013Applicant: GILEAD PHARMASSET LLCInventor: GILEAD PHARMASSET LLC
-
Patent number: 6569929Abstract: The present invention relates to a method for preparing phosphoramides having a glass transition temperature in one embodiment of at least about 0° C., in another embodiment of at least about 10° C., and in still another embodiment of at least about 20° C., the phosphoramides being substantially free of acidic, basic, or halide impurities, or their precursors. The invention also relates to resin compositions comprising at least one thermoplastic resin and at least one phosphoramide having a glass transition temperature of at least about 0° C., wherein the phosphoramide is prepared by the method of the invention.Type: GrantFiled: May 4, 2001Date of Patent: May 27, 2003Assignee: General Electric CompanyInventors: Neal Steven Falcone, John Robert Campbell, James Ross Fishburn
-
Patent number: 6528559Abstract: This invention provides a halogen-free flame retardant which advantageously has a high melting point and a low volatility and does not impair the inherent properties of resins. The flame retardant of the invention is a phosphazene compound crosslinked with a crosslinking group such as a phenylene group, wherein each of the crosslinking groups is interposed between the two oxygen groups left after the elimination of phenyl groups from the phosphazene compound; the crosslinked phenoxyphosphazene compound does not have any free hydroxyl groups (derived from crosslinking groups); and the amount of the phenyl groups in the crosslinked compound is 50 to 99.9%, based on the total number of the phenyl groups in the phosphazene compound.Type: GrantFiled: February 12, 2001Date of Patent: March 4, 2003Assignee: Otsuka Chemical Co., Ltd.Inventors: Yoshifumi Nakacho, Tadao Yabuhara, Yuji Tada, Yoichi Nishioka
-
Patent number: 6384261Abstract: Phosphoramidates and phosphinic amides and related compounds are provided. Also provided are methods that use the compounds for modulating the activity of the endothelin family of peptides are provided. In particular, compounds having formula: in which A, B, R1 and R2 are as described are provided. Also provided are methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these compounds or prodrugs thereof. Methods for elucidating the physiological and pathophysiological roles of endothelin, as well as isolating endothelin receptors are also provided.Type: GrantFiled: September 3, 1998Date of Patent: May 7, 2002Assignee: Texas Biotechnology CorporationInventors: Ming Fai Chan, Erik Joel Verner
-
Patent number: 5840917Abstract: A phosphorylamide derivative represented by the general formula (I): ##STR1## wherein R represents an amino group that may be substituted, or a salt thereof, possesses potent antibacterial activity against Helicobacter bacterium, especially Helicobacter pylori, and is useful for prevention or treatment of digestive diseases caused by Helicobacter bacterium, solely or in combination with an antacid or an acid secretion inhibitor.Type: GrantFiled: December 6, 1996Date of Patent: November 24, 1998Assignee: Takeda Chemical Industries, Ltd.Inventors: Satoru Oi, Hideaki Nagaya, Nobuhiro Inatomi, Masafumi Nakao, Hidefumi Yukimasa
-
Patent number: 5550276Abstract: Compounds of the general formula I ##STR1## in which n is 1, 2 or 3 and in which X is oxygen or sulfur, T has the meaning of --S--, --S--S--, --S--S--, --S--S--S--S--, --S--S--S--S--S--, ##STR2## and Y has the meaning of ##STR3## in which Z has the meaning of --H, --COR.sup.13, --COOR.sup.13 or --CONHR.sup.13, and Q has the meaning of oxygen or --NR.sup.0 --, and R.sup.1, R.sup.2, R.sup.0, R.sup.4 and R.sup.13 are as defined in claim 1, with the proviso that the compound of the formula C.sub.2 H.sub.5 --S--CH.sub.2 CH(OH)--P(OC.sub.2 H.sub.5).sub.2 is excepted.The invention also relates to compositions containing the compounds of the formula I and organic materials, for example functional liquids and, in particular, lubricants.Type: GrantFiled: June 7, 1995Date of Patent: August 27, 1996Assignee: Ciba-Geigy CorporationInventors: Hermann O. Wirth, Hans-Helmut Friedrich, Kay S. Groninger
-
Polyphosphazene derivatives containing carbonyl groups and variously alkylated tertiary amino groups
Patent number: 5260103Abstract: Polyphosphazene derivatives containing carbonyl groups and variously alkylated tertiary aminic groups, suited to undergo rapid and efficient photo-crosslinking processes and having general formula: ##STR1## wherein: X represents substituents linked to the polyphosphazene chain by means of hydroxylic or aminic functions and containing carbonyl groups;X' represents additional substituents linked to the polyphosphazene chain by means of hydroxylic or aminic functions and containing one or more variously alkylated tertiary aminic groups;(w+y+z) is an integer ranging from 20 to 15,000;w and z are integers having a value higher than or equal to zero and at any rate lower than 15,000;y is an integer having a value of from 20 to 15,000.Type: GrantFiled: July 17, 1990Date of Patent: November 9, 1993Assignee: Consiglio Nazionale Delle RicercheInventors: Mario Gleria, Francesco Minto, Lucia Flamigni -
Patent number: 5205852Abstract: Herbicidal compounds have the formula ##STR1## in which R is C.sub.3 -C.sub.6 alkyl or C.sub.3 -C.sub.6 cycloalkyl;X is oxygen or sulfur;R.sub.1 is C.sub.1 -C.sub.12 alkyl, C.sub.3 -C.sub.6 cycloalkyl optionally substituted with up to two C.sub.1 -C.sub.3 alkyl groups, phenyl, or substituted phenyl having from 1 to 2 substituents selected from halo, nitro, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 thioalkyl, C.sub.3 -C.sub.4 alkenyl, C.sub.1 -C.sub.4 alkoxycarbonyl, and phenyl;R.sub.2 is hydrogen, C.sub.1 -C.sub.6 alkyl or C.sub.3 -C.sub.6 cycloalkyl; andR.sub.3 is C.sub.2 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, phenyl or substituted phenyl having from 1 to 2 substituents selected from C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 haloalkyl and halogen;provided that if R.sub.2 is hydrogen, R.sub.3 is not phenyl or substituted phenyl;or R.sub.2 and R.sub.3 taken together with the nitrogen atom form a 4-8 membered ring, optionally including an oxygen heteroatom.Type: GrantFiled: November 12, 1991Date of Patent: April 27, 1993Assignee: Imperial Chemical Industries PLCInventors: Michael D. Broadhurst, Tsze H. Tsang
-
Patent number: 5189169Abstract: Herbicides having the formula ##STR1## in which X is oxygen or sulfur; and if X is sulfur, R.sub.1 is C.sub.1 -C.sub.6 alkyl, C.sub.5 -C.sub.6 cycloalkyl, allyl, phenyl, tolyl, chlorophenyl, 3,4-dichlorophenyl, or phen-(C.sub.1 -C.sub.2)alkyl; R.sub.2 is C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkoxyalkyl, or allyl; R.sub.3 is C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxyalkyl, pyridyl, phenyl or substituted phenyl in which the substituents are halogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 haloalkoxy, nitro and/or cyano; or R.sub.2 and R.sub.3 taken together form an alkylene chain having from 2 to 6 carbon atoms optionally substituted by up to two C.sub.1 -C.sub.4 alkyl groups; if R.sub.3 is alkyl or alkoxyalkyl, then R.sub.4 and R.sub.5 are each C.sub.2 -C.sub.4 alkyl; if R.sub.3 is phenyl, substituted phenyl or pyridyl, then R.sub.4 and R.sub.5 are C.sub.2 -C.sub. 6 alkyl, phenyl or substituted phenyl; or R.sub.3 and R.sub.Type: GrantFiled: November 12, 1991Date of Patent: February 23, 1993Assignee: Imperial Chemical Industries PLCInventor: David B. Kanne
-
Patent number: 5187266Abstract: A compound having the structure: ##STR1## wherein R is CH.sub.3, C.sub.2 H.sub.5, C.sub.3 H.sub.7, t-C.sub.4 H.sub.9 or C.sub.6 H.sub.5 ; R.sup.1 is NH.sub.2, NHCH.sub.3, NHC.sub.2 H.sub.5, NHC.sub.3 H.sub.7, NHC.sub.4 H.sub.9, NHCH.sub.2 CH.sub.2 Cl, NHC.sub.6 H.sub.5, N(CH.sub.3).sub.2, N(C.sub.2 H.sub.5).sub.2, N(C.sub.3 H.sub.7).sub.2, NCH.sub.3 (C.sub.2 H.sub.5), NCH.sub.3 (C.sub.3 H.sub.7), N(CH.sub.2 CH.sub.2 Cl).sub.2, NHOH, NHNHCO.sub.2 CH.sub.2 C.sub.6 H.sub.5, NHNHCO.sub.2 C(CH.sub.3).sub.3, OCH.sub.3, OC.sub.2 H.sub.5, OC.sub.3 H.sub.7, OC.sub.4 H.sub.9, OC.sub.6 H.sub.5, OC.sub.2 C.sub.6 H.sub.5, CH.sub.3, C.sub.2 H.sub.5, C.sub.3 H.sub.7, C.sub.4 H.sub.9, CH.sub.2 NO.sub.2 or CH.sub.2 NH.sub.2 ; and R.sup.2 is NHCH.sub.2 CH.sub.2 Cl or N(CH.sub.2 CH.sub.2 Cl).sub.2.These compounds may be used to eliminate occult leukemic clonogenic cells from bone marrow by contacting the bone marrow with a solution comprising levels of said compound sufficient to eliminate occult leukemic clonogenic cells.Type: GrantFiled: February 24, 1992Date of Patent: February 16, 1993Assignee: Board of Regents the University of Texas SystemInventors: David Farquhar, Yugiang Wang
-
Patent number: 5091552Abstract: A compound having the structure: ##STR1## wherein R is CH.sub.3, C.sub.2 H.sub.5, C.sub.3 H.sub.7, t--C.sub.4 H.sub.9 or C.sub.6 H.sub.5 ; R.sup.1 is NH.sub.2, NHCH.sub.3, NHC.sub.2 H.sub.5, NHC.sub.3 H.sub.7, NHC.sub.4 H.sub.9, NHCH.sub.2 CH.sub.2 Cl, NHC.sub.6 H.sub.5, N(CH.sub.3).sub.2, N(C.sub.2 H.sub.5).sub.2, N(C.sub.3 H.sub.7).sub.2, NCH.sub.3 (C.sub.2 H.sub.5), NCH.sub.3 (C.sub.3 H.sub.7), N(CH.sub.2 CH.sub.2 Cl).sub.2, NHOH, NHNHCO.sub.2 CH.sub.2 C.sub.6 H.sub.5, NHNHCO.sub.2 C(CH.sub.3).sub.3, OCH.sub.3, OC.sub.2 H.sub.5, OC.sub.3 H.sub.7, OC.sub.4 H.sub.9, OC.sub.6 H.sub.5, OC.sub.2 C.sub.6 H.sub.5, CH.sub.3, C.sub.2 H.sub.5, C.sub.3 H.sub.7, C.sub.4 H.sub.9, CH.sub.2 NO.sub.2 or CH.sub.2 NH.sub.2 ; and R.sup.2 is NHCH.sub.2 CH.sub.2 Cl or N(CH.sub.2 CH.sub.2 Cl).sub.2.These compounds may be used to eliminate occult leukemic clonogenic cells from bone marrow by contacting the bone marrow with a solution comprising levels of said compound sufficient to eliminate occult leukemic clonogenic cells.Type: GrantFiled: March 14, 1989Date of Patent: February 25, 1992Assignee: Board of Regents, The University of Texas SystemInventor: David Farquhar
-
Patent number: 4652648Abstract: Phosphonous acid monoester-monoamides of the formula ##STR1## in which n is 1, R.sub.1 is phenyl, R.sub.2, R.sub.3 and R.sub.4 are independently hydrogen or alkyl, R.sub.5 is alkyl or cyclohexyl, R.sub.6 is 2,2,6,6-tetramethylpiperidin-4-yl or ##STR2## R.sub.3 may also be ##STR3## where X is methylene or isopropylidene and R.sub.6 is alkyl or cyclohexyl. Said compounds are suitable for protecting organic material from the harmful effect of heat, oxygen and light.Type: GrantFiled: November 13, 1985Date of Patent: March 24, 1987Assignee: Ciba-Geigy CorporationInventor: Michael Rasberger